Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
boston blog main
9
×
national blog main
boston top stories
life sciences
san francisco blog main
san francisco top stories
biotech
indiana blog main
indiana top stories
national top stories
new york blog main
new york top stories
raleigh-durham blog main
raleigh-durham top stories
boulder/denver blog main
boulder/denver top stories
detroit blog main
detroit top stories
national
san diego blog main
san diego top stories
sanofi
seattle blog main
seattle top stories
texas blog main
texas top stories
wisconsin blog main
wisconsin top stories
eli lilly
fda
bristol-myers squibb
cancer
deals
ipo
clinical trials
drug prices
medicare
merck
novartis
pfizer
What
pharmaceutical
9
×
bio
roundup
cancer
drug
new
american
based
best
companies
continue
crash
debate
drugs
eli
giant
hasn’t
healthcare
industry
kind
latest
medicines
nash
people
policy
politicians
pressure
prices
scalps
second
trump’s
typically
u.s
acute
addresses
alzheimer’s
appetite
approval
away
bails
Language
unset
Current search:
pharmaceutical
×
" boston blog main "
×
@xconomy.com
4 years ago
Revolution Medicines Maps Out an IPO to Reach Cancer’s Frontiers
@xconomy.com
4 years ago
Bio Roundup: Ichnos Emerges, Beyond CAR-T, BridgeBio Bails & More
@xconomy.com
4 years ago
FDA OKs Lilly’s Lasmiditan, First New Acute Migraine Drug in Decades
@xconomy.com
5 years ago
Pharma CEOs to Senate: We Will Lower Drug Prices if Rebates Go Away
@xconomy.com
5 years ago
Bio Roundup: Trump’s Scalps, Policy Pressure, NASH Crash & More
@xconomy.com
5 years ago
Bio Roundup: Trump’s Scalps, Policy Pressure, NASH Crash & More
@xconomy.com
5 years ago
Bio Roundup: Alzheimer’s Fail, Drug Price Plan, Gene Therapies & More
@xconomy.com
5 years ago
Bio Roundup: #JPM19 Notes, Loxo Buyout, Black Diamond’s Cash & More
@xconomy.com
5 years ago
With $45M Translate Bio Deal, Sanofi Bets Again on mRNA Vaccines